Ultragenyx to Participate at Investor Conferences in September
Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare genetic disease therapies, has announced its participation in three major investor conferences in September 2025.
The company's leadership, including Chief Medical Officer Eric Crombez, M.D. and Chief Financial Officer Howard Horn, will participate in fireside chats and host one-on-one meetings at the Cantor Global Healthcare Conference (September 4), Morgan Stanley Global Healthcare Conference (September 9), and Bank of America Global Healthcare Conference (September 23). All fireside chat sessions will be available via webcast on the company's investor relations website.
Ultragenyx Pharmaceutical (NASDAQ: RARE), azienda biofarmaceutica specializzata in terapie per malattie genetiche rare e ultra-rare, ha comunicato la sua partecipazione a tre importanti conferenze per investitori a settembre 2025.
La leadership dell’azienda, tra cui il Chief Medical Officer Eric Crombez, M.D. e il Chief Financial Officer Howard Horn, prenderà parte a fireside chat e terrà incontri one-to-one al Cantor Global Healthcare Conference (4 settembre), al Morgan Stanley Global Healthcare Conference (9 settembre) e al Bank of America Global Healthcare Conference (23 settembre). Tutte le sessioni di fireside chat saranno trasmesse via webcast sul sito delle relazioni con gli investitori dell’azienda.
Ultragenyx Pharmaceutical (NASDAQ: RARE), una compañía biofarmacéutica especializada en terapias para enfermedades genéticas raras y ultrarraras, ha anunciado su participación en tres importantes conferencias para inversores en septiembre de 2025.
La dirección de la empresa, entre ellos el Chief Medical Officer Eric Crombez, M.D. y el Chief Financial Officer Howard Horn, participará en conversaciones informales (fireside chats) y mantendrá reuniones individuales en el Cantor Global Healthcare Conference (4 de septiembre), el Morgan Stanley Global Healthcare Conference (9 de septiembre) y el Bank of America Global Healthcare Conference (23 de septiembre). Todas las sesiones de fireside chat estarán disponibles por webcast en la web de relaciones con inversores de la compañía.
Ultragenyx Pharmaceutical (NASDAQ: RARE)는 희귀 및 초희귀 유전질환 치료제에 특화된 바이오제약사로, 2025년 9월 개최되는 주요 투자자 컨퍼런스 세 곳에 참여한다고 발표했습니다.
회사 경영진인 Chief Medical Officer Eric Crombez, M.D.와 Chief Financial Officer Howard Horn이 Cantor Global Healthcare Conference(9월 4일), Morgan Stanley Global Healthcare Conference(9월 9일), Bank of America Global Healthcare Conference(9월 23일)에서 파이어사이드 채팅에 참여하고 일대일 미팅을 진행합니다. 모든 파이어사이드 채팅은 회사 투자자관계 웹사이트에서 웹캐스트로 시청할 수 있습니다.
Ultragenyx Pharmaceutical (NASDAQ: RARE), une société biopharmaceutique spécialisée dans les thérapies pour maladies génétiques rares et ultra-rares, a annoncé sa participation à trois grandes conférences investisseurs en septembre 2025.
La direction de l'entreprise, incluant le Chief Medical Officer Eric Crombez, M.D. et le Chief Financial Officer Howard Horn, participera à des conversations informelles (fireside chats) et tiendra des rencontres individuelles lors du Cantor Global Healthcare Conference (4 septembre), du Morgan Stanley Global Healthcare Conference (9 septembre) et du Bank of America Global Healthcare Conference (23 septembre). Toutes les sessions de fireside chat seront diffusées en webcast sur le site relations investisseurs de la société.
Ultragenyx Pharmaceutical (NASDAQ: RARE), ein biopharmazeutisches Unternehmen, das sich auf Therapien für seltene und sehr seltene genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an drei großen Investorenkonferenzen im September 2025 angekündigt.
Die Unternehmensleitung, darunter Chief Medical Officer Eric Crombez, M.D. und Chief Financial Officer Howard Horn, wird an Fireside-Chats teilnehmen und Einzelgespräche beim Cantor Global Healthcare Conference (4. September), dem Morgan Stanley Global Healthcare Conference (9. September) und dem Bank of America Global Healthcare Conference (23. September) führen. Alle Fireside-Chat-Sitzungen werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
NOVATO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in three upcoming investor conferences.
Cantor Global Healthcare Conference 2025 (New York, NY)
- Thursday, September 4, 2025, Eric Crombez, M.D., Chief Medical Officer and Howard Horn, Chief Financial Officer, will participate in a fireside chat and host 1x1 meetings.
Morgan Stanley 23rd Annual Global Healthcare Conference (New York, NY)
- Tuesday, September 9, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
Bank of America Global Healthcare Conference (London, UK)
- Tuesday, September 23, 2025, Eric Crombez will participate in a fireside chat and host 1x1 meetings.
The live and archived webcast of the fireside chats will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
FAQ
When is Ultragenyx (RARE) presenting at the Cantor Global Healthcare Conference 2025?
Who will represent Ultragenyx at the September 2025 healthcare conferences?
How can investors access Ultragenyx's conference presentations in September 2025?
Which investor conferences will Ultragenyx (RARE) attend in September 2025?
